Evidence map›Paper›PMID 35047863›Full record

ArticleHGG advances2022

A whole-exome case-control association study to characterize the contribution of rare coding variation to pancreatic cancer risk.

Yao Yu, Kyle Chang, Jiun-Sheng Chen, Ryan J Bohlender, Jerry Fowler, Di Zhang, Maosheng Huang, Ping Chang, Yanan Li, Justin Wong and 12 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in HGG advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 6 institutions in 2 countries.

Yao YuDepartment of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kyle ChangDepartment of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jiun-Sheng ChenDepartment of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ryan J BohlenderDepartment of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jerry FowlerDepartment of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Di ZhangDepartment of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Maosheng HuangDepartment of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ping ChangDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yanan LiDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Justin WongDepartment of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Huamin WangDepartment of Anatomical Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jian GuDepartment of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Xifeng WuCenter for Clinical Big Data and Analytics, Bioinformatics and Big Data, The Second Affiliated Hospital and School of Public Health, Zhejiang University School of Medicine, PR China.
Joellen SchildkrautDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
Lisa Cannon-AlbrightGenetic Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA.
Yuanqing YeCenter for Clinical Big Data and Analytics, Bioinformatics and Big Data, The Second Affiliated Hospital and School of Public Health, Zhejiang University School of Medicine, PR China.
Hua ZhaoDepartment of Family Medicine and Population Health, School of Medicine, Virginia Commonwealth University, Richmond, VA, USA.
Michelle A T HildebrandtDepartment of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jennifer B PermuthDepartments of Cancer Epidemiology and Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Donghui LiDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Paul ScheetDepartment of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Chad D HuffDepartment of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
The University of Texas MD Anderson Cancer Center · USZhejiang University · CNEmory University · USMoffitt Cancer Center · USUniversity of Utah · USVirginia Commonwealth University · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI KENNETH Lynn WRIGHT · 1998 to 2026
$93.5M
Discovery of Novel Rare Variants as Ovarian Cancer Susceptibility FactorsR01CA188943 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HILDEBRANDT, MICHELLE A T, HUFF, CHAD DANIEL · 2015 to 2019
$5.5M
Discovery of Risk Loci and Genomics of Pancreatic Cancer through Exome SequencingR01CA181244 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HUFF, CHAD DANIEL, SCHEET, PAUL A · 2014 to 2019
$5.4M
High-throughput sequencing to identify novel melanoma susceptibility genesR01CA195614 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ALBRIGHT, LISA CANNON, HUFF, CHAD DANIEL · 2015 to 2019
$5.4M
Next generation sequencing to identify novel colorectal cancer genesR01CA177935 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HUFF, CHAD DANIEL, YE, YUANQING · 2014 to 2018
$3.3M
Harnessing the power of genetic relatedness for disease gene discoveryR01GM133169 · NIGMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BELOW, JENNIFER, HUFF, CHAD DANIEL · 2019 to 2022
$2.6M
NovaSeq6000S10OD024977 · OD · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HUFF, VICKI · 2018 to 2018
$995k
NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA076292NCI NIH HHS R01 CA177935NCI NIH HHS R01 CA181244NCI NIH HHS R01 CA188943NCI NIH HHS R01 CA195614NIGMS NIH HHS R01 GM133169NIH HHS S10 OD024977
6 · The paper itself

Abstract

Pancreatic cancer is a deadly disease that accounts for approximately 5% of cancer deaths worldwide, with a dismal 5-year survival rate of 10%. Known genetic risk factors explain only a modest proportion of the heritable risk of pancreatic cancer. We conducted a whole-exome case-control sequencing study in 1,591 pancreatic cancer cases and 2,134 cancer-free controls of European ancestry. In our gene-based analysis,

Indexed as

Association AnalysisATMCase-Control StudyPancreatic CancerSIK3

Identifiers

PMID35047863
PMCPMC8756505
OpenAlexW4200163624

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.